Related Experiment Videos
The design, structure, and therapeutic application of matrix metalloproteinase inhibitors
J W Skiles1, N C Gonnella, A Y Jeng
1Novartis Institute for Biomedical Research, 556 Morris Avenue, Summit, NJ 07901, USA.
Abstract:
Matrix metalloproteinases (MMPs) are a family of zinc-containing enzymes involved in the degradation and remodeling of extracellular matrix proteins. The activities of these enzymes are well regulated by endogenous tissue inhibitors of metalloproteinases (TIMPs). Chronic stimulation of MMP activities due to an imbalance in the levels of MMPs and TIMPs has been implicated in the pathogenesis of a variety of diseases such as cancer, osteoarthritis, and rheumatoid arthritis. Thus, MMP inhibitors are expected to be useful for the treatment of these disorders. This article reviews briefly the biochemistry of MMPs and evidence for their pathogenic roles using molecular biology approaches. Biomolecular structures used in the design of MMP inhibitors are thoroughly covered. Major emphasis is on recently published potent, small molecular weight MMP inhibitors and their pharmacological properties. Finally, available clinical results of compounds in development are summarized.
Insights
Matrix metalloproteinases (MMPs) are enzymes implicated in diseases like cancer and arthritis. MMP inhibitors, targeting these enzymes, show promise for treating such disorders, with ongoing clinical trials evaluating their efficacy.
Area of Science:
- Biochemistry
- Molecular Biology
- Pharmacology
Background:
- Matrix metalloproteinases (MMPs) are zinc-dependent enzymes crucial for extracellular matrix remodeling.
- An imbalance between MMPs and their inhibitors (TIMPs) is linked to diseases like cancer and arthritis.
- MMPs play significant roles in disease pathogenesis, making them therapeutic targets.
Purpose of the Study:
- To review the biochemistry of MMPs and their pathogenic roles.
- To cover biomolecular structures utilized in designing MMP inhibitors.
- To summarize recent potent MMP inhibitors, their properties, and clinical outcomes.
Main Methods:
- Review of scientific literature on MMPs and their inhibitors.
- Analysis of molecular biology evidence for MMPs' roles in disease.
- Examination of structural data for MMP inhibitor design.
- Summary of pharmacological data and clinical trial results for MMP inhibitors.
Main Results:
- MMPs are key enzymes in matrix degradation, and their dysregulation contributes to various diseases.
- Small molecule MMP inhibitors have been developed with potent pharmacological properties.
- Several MMP inhibitors are in clinical development for treating MMP-associated disorders.
Conclusions:
- MMP inhibitors represent a promising therapeutic strategy for diseases involving MMP dysregulation.
- Understanding MMP structure and function is critical for designing effective inhibitors.
- Further clinical evaluation is ongoing to establish the therapeutic value of MMP inhibitors.